Obesity: A Focus on Pharmacotherapy

被引:0
|
作者
Wong, Elaine [1 ]
Kaur, Navneet [2 ]
Ma, Nicholas [2 ]
Patel, Kinjal [2 ]
Ringel, Moshe [2 ]
机构
[1] Long Isl Univ, Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA
来源
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2013年 / 9卷 / 06期
关键词
diethylpropion; lorcaserin; obesity; orlistat; phentermine; phentermine/topiramate; WEIGHT-LOSS; CONTROLLED-RELEASE; OVERWEIGHT ADULTS; LORCASERIN; TRIAL;
D O I
10.1016/j.nurpra.2013.03.015
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Obesity is a condition associated with a vast number of health complications. Clinicians should initially counsel obese patients (defined as a body mass index >= 30 kg/m(2)) on lifestyle modifications to achieve and sustain weight loss. The addition of pharmacologic therapy can be considered in patients who do not have satisfactory outcomes with this approach. Currently, several pharmacologic therapies have received Food and Drug Administration approval. This article reviews pharmacologic data and relevant clinical literature with which a nurse practitioner should be familiar when prescribing and evaluating the safety and efficacy of weight loss medications in obese patients.
引用
收藏
页码:387 / 395
页数:9
相关论文
共 50 条
  • [41] Advances in pharmacotherapy for obesity
    Carruba, M
    Tomello, C
    Briscini, L
    Nisoli, E
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 : S13 - S16
  • [42] Pharmacotherapy in Childhood Obesity
    Kuhnen, Peter
    Biebermann, Heike
    Wiegand, Susanna
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (02): : 177 - 192
  • [43] Pharmacotherapy for Patients with Obesity
    Gadde, Kishore M.
    Apolzan, John W.
    Berthoud, Hans-Rudolf
    CLINICAL CHEMISTRY, 2018, 64 (01) : 118 - 129
  • [44] Pharmacotherapy for obesity: moving towards efficacy improvement
    Coutinho, Walmir
    Halpern, Bruno
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01)
  • [45] Recent progress and novel perspectives on obesity pharmacotherapy
    Faria, Andre M.
    Mancini, Marcio C.
    de Melo, Maria Edna
    Cercato, Cintia
    Halpern, Alfredo
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2010, 54 (06) : 516 - 529
  • [46] The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
    Mancini, Marcio C.
    de Melo, Maria Edna
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [47] Pharmacotherapy for the treatment of obesity
    Sweeting, Arianne N.
    Hocking, Samantha L.
    Markovic, Tania P.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 : 173 - 183
  • [48] Interface between Pharmacotherapy and Genes in Human Obesity
    O'Connor, Annalouise
    Swick, Andrew G.
    HUMAN HEREDITY, 2013, 75 (2-4) : 116 - 126
  • [49] Pharmacotherapy for obesity: moving towards efficacy improvement
    Walmir Coutinho
    Bruno Halpern
    Diabetology & Metabolic Syndrome, 16
  • [50] Cardiometabolic Effects of Anti-obesity Pharmacotherapy
    Crawford, Andrew R.
    Alamuddin, Naji
    Amaro, Anastassia
    CURRENT ATHEROSCLEROSIS REPORTS, 2018, 20 (04)